HL Genomics

HL Genomics is a chemical-synthesis API specialist established in November 2000 by Halim Pharmaceutical to internalize its upstream raw-material supply chain; its headquarters and first manufacturing plant are in Cheoin-gu, Yongin, Gyeonggi Province, under CEO Ho-jin Kim.

Three core products define the portfolio: pitavastatin calcium (dyslipidemia), S-amlodipine nicotinate (hypertension), and bepotastine besilate (allergic rhinitis), each produced through high-purity crystallization and impurity-profile control technologies.

Based on 2025 revenue, cardiovascular contributed 45.2%, respiratory 27.6%, musculoskeletal 7.9%, and neurological 7.3%, with the top two segments representing 72.8% of sales.

A structural feature of the Korean API market—regulatory requirements for re-filing when switching approved suppliers—creates inherent customer stickiness that supports recurring revenue.

Halim Pharmaceutical is the dominant customer, averaging 48.8% of revenue over 2023–2025 and reaching 59.2% in 1Q 2026; the company has shifted to three-year long-term supply agreements to improve order visibility.

External clients—other finished-drug manufacturers, wholesalers, and export accounts—comprise approximately 40–50% of revenue, with diversification efforts ongoing.

As of 2025, the company holds 23 Drug Master File (KDMF) registrations with Korea's MFDS and has a track record of passing PMDA inspections in Japan, providing a partial foundation for overseas expansion.

A new growth avenue is a June 2023 exclusive CMO partnership with DDS firm Quad Medicine for three vaccine candidates, positioning HL Genomics to enter the vaccine microneedle production market. As of mid-2026, the company employed 58 people with paid-in capital of KRW 3.0 bn—a lean, high-margin specialty manufacturer.

For FY2025 on a consolidated basis, revenue reached KRW 28.9 bn (+2.5% year-on-year), operating profit KRW 9.3 bn (OPM 32.3%), and net profit KRW 8.5 bn, extending the unbroken profit streak to 19 consecutive years.

Revenue grew at a three-year CAGR of approximately 10%, but annual growth decelerated sharply from 13.5% in 2024 to 2.5% in 2025 and ~2.4% in 1Q 2026.

First-quarter 2026 revenue of KRW 8.4 bn and operating profit of KRW 2.9 bn represented year-on-year gains of 2.3% and 7.1%, respectively—profitability was preserved, but top-line expansion remained constrained.

The structural driver of the slowdown is first-plant saturation: utilization of 106.1% in 2023, 124.0% in 2024, and 117.8% in 2025 has left virtually no incremental capacity for new orders.

Management has partially offset this through process engineering—shortening production cycles from 15 to 11 days and raising per-batch output from 20 kg to 27 kg—extracting more throughput from the same fixed assets.

From a balance-sheet perspective, the company carries no external debt, with a debt-to-equity ratio of approximately 6–7% and a current ratio of 1,084%, far exceeding sector averages, reflecting its strong cash generation.

The IPO attracted institutional book demand of 714.5x and retail subscriptions of 667.2x, with aggregate subscription deposits of approximately KRW 4.6 tn, setting the final price at the top of the range, KRW 21,500.

On listing day, the stock rose to an intraday high of KRW 25,550 (+18.8%) before a market-wide crash—KOSPI -5.72%, KOSDAQ -5.32%—triggered by oil prices re-crossing USD 100/barrel and a U.S. tech sell-off drove it to close at KRW 14,790, down 31.21% from the IPO price.

The low institutional voluntary lock-up rate of just 1.9% of book-build volume amplified the supply pressure on listing day.

The central medium-term growth catalyst is the second-plant expansion.

A total of KRW 76.5 bn will be invested to build the Yongin facility—groundbreaking 3Q 2026, structural completion 4Q 2027, regulatory approvals and qualification audits through end-2028, and commercial production commencing in 2029—which would expand capacity by up to 2x.

EU-GMP-compliant construction and automation investments are expected to lift production efficiency and establish a platform for direct export to European and global markets.

On new-business development, the company aims to commercialize CDMO services via small-scale multi-line reactors, transitioning toward a high-value, full-service model spanning research, process development, clinical supply, and commercial manufacturing.

The vaccine microneedle CMO partnership with Quad Medicine has cleared milestones including grant funding from an international aid organization and execution of material transfer agreements, but commercial production is contingent on the clinical outcomes of Quad Medicine's vaccine candidates and completion of a dedicated production suite within the new plant.

The government's expanded domestic-API drug-pricing premium program could incentivize more finished-drug makers to shift API sourcing domestically, broadening HL Genomics' addressable market.

A near-term headwind is annual depreciation of up to KRW 3.6 bn post-completion of the second plant, which will be recognized before commercial revenues begin.

Captive reliance on Halim Pharmaceutical will remain structurally unavoidable through 2029, and the pace of external customer diversification and CDMO order accumulation will be the pivotal determinants of long-run earnings trajectory.